Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome
Systemic sclerosis (SSc) may overlap with systemic lupus erythematous (SLE). Little is known about the epidemiology, clinical characteristics, and survival of SSc-SLE overlap. We evaluated the prevalence of SSc-SLE overlap and differences in SSc characteristics, and compared survival with SSc withou...
Saved in:
| Published in | Journal of rheumatology Vol. 45; no. 10; p. 1406 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Canada
01.10.2018
|
| Subjects | |
| Online Access | Get more information |
Cover
Loading…
| Abstract | Systemic sclerosis (SSc) may overlap with systemic lupus erythematous (SLE). Little is known about the epidemiology, clinical characteristics, and survival of SSc-SLE overlap. We evaluated the prevalence of SSc-SLE overlap and differences in SSc characteristics, and compared survival with SSc without SLE.
A cohort study was conducted including subjects who fulfilled the American College of Rheumatology (ACR)/European League Against Rheumatism classification criteria for SSc and/or the ACR criteria for SLE. The primary outcome was time from diagnosis to all-cause mortality. Survival was evaluated using Kaplan-Meier and Cox proportional hazard models.
We identified 1252 subjects (SSc: n = 1166, SSc-SLE: n = 86) with an SSc-SLE prevalence of 6.8%. Those with SSc-SLE were younger at diagnosis (37.9 yrs vs 47.9 yrs, p < 0.001), more frequently East Asian (5.5% vs 20%) or South Asian (5.1% vs 12%), had lupus anticoagulant (6% vs 0.3%, p < 0.001), anticardiolipin antibody (6% vs 0.9%, p < 0.001), and pulmonary arterial hypertension (PAH; 52% vs 31%, p < 0.001). Those with SSc-SLE less frequently had calcinosis (13% vs 27%, p = 0.007), telangiectasia (49% vs 75%, p < 0.001), and diffuse subtype (12% vs 35%, p < 0.001). There were no significant differences in the occurrence of renal crisis (7% vs 7%), interstitial lung disease (ILD; 41% vs 34%), and digital ulcers (38% vs 32%). Those with SSc-SLE had better median survival time (26.1 vs 22.4 yrs), but this was not statistically significant (log-rank p = 0.06). Female sex and diffuse subtype attenuated survival differences between groups (HR 1.07, 95% CI 0.67-1.67).
Patients with SSc-SLE are younger at diagnosis, more frequently have PAH, and less frequently have cutaneous manifestations of SSc. They should be monitored for ILD, renal crisis, and digital ulcers. |
|---|---|
| AbstractList | Systemic sclerosis (SSc) may overlap with systemic lupus erythematous (SLE). Little is known about the epidemiology, clinical characteristics, and survival of SSc-SLE overlap. We evaluated the prevalence of SSc-SLE overlap and differences in SSc characteristics, and compared survival with SSc without SLE.
A cohort study was conducted including subjects who fulfilled the American College of Rheumatology (ACR)/European League Against Rheumatism classification criteria for SSc and/or the ACR criteria for SLE. The primary outcome was time from diagnosis to all-cause mortality. Survival was evaluated using Kaplan-Meier and Cox proportional hazard models.
We identified 1252 subjects (SSc: n = 1166, SSc-SLE: n = 86) with an SSc-SLE prevalence of 6.8%. Those with SSc-SLE were younger at diagnosis (37.9 yrs vs 47.9 yrs, p < 0.001), more frequently East Asian (5.5% vs 20%) or South Asian (5.1% vs 12%), had lupus anticoagulant (6% vs 0.3%, p < 0.001), anticardiolipin antibody (6% vs 0.9%, p < 0.001), and pulmonary arterial hypertension (PAH; 52% vs 31%, p < 0.001). Those with SSc-SLE less frequently had calcinosis (13% vs 27%, p = 0.007), telangiectasia (49% vs 75%, p < 0.001), and diffuse subtype (12% vs 35%, p < 0.001). There were no significant differences in the occurrence of renal crisis (7% vs 7%), interstitial lung disease (ILD; 41% vs 34%), and digital ulcers (38% vs 32%). Those with SSc-SLE had better median survival time (26.1 vs 22.4 yrs), but this was not statistically significant (log-rank p = 0.06). Female sex and diffuse subtype attenuated survival differences between groups (HR 1.07, 95% CI 0.67-1.67).
Patients with SSc-SLE are younger at diagnosis, more frequently have PAH, and less frequently have cutaneous manifestations of SSc. They should be monitored for ILD, renal crisis, and digital ulcers. |
| Author | Touma, Zahi Mitsakakis, Nicholas Johnson, Sindhu R Bookman, Arthur A Ahmad, Zareen Sanchez-Guerrero, Jorge Alharbi, Samar |
| Author_xml | – sequence: 1 givenname: Samar surname: Alharbi fullname: Alharbi, Samar organization: S. Alharbi, MD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, and Division of Rheumatology, Mount Sinai Hospital, University of Toronto, and Taibah University; Z. Ahmad, MD, Division of Rheumatology, Mount Sinai Hospital, University of Toronto; A.A. Bookman, MD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network; Z. Touma, MD, PhD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, and Institute of Health Policy, Management and Evaluation, University of Toronto; J. Sanchez-Guerrero, MD, MSc, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, and Division of Rheumatology, Mount Sinai Hospital, University of Toronto; N. Mitsakakis, PhD, Institute of Health Policy, Management and Evaluation, and Toronto Health Economics and Technology Assessment Collaborative, University of Toronto; S.R. Johnson, MD, PhD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, University of Toronto, and Division of Rheumatology, Mount Sinai Hospital, and Institute of Health Policy, Management and Evaluation, University of Toronto – sequence: 2 givenname: Zareen surname: Ahmad fullname: Ahmad, Zareen organization: S. Alharbi, MD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, and Division of Rheumatology, Mount Sinai Hospital, University of Toronto, and Taibah University; Z. Ahmad, MD, Division of Rheumatology, Mount Sinai Hospital, University of Toronto; A.A. Bookman, MD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network; Z. Touma, MD, PhD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, and Institute of Health Policy, Management and Evaluation, University of Toronto; J. Sanchez-Guerrero, MD, MSc, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, and Division of Rheumatology, Mount Sinai Hospital, University of Toronto; N. Mitsakakis, PhD, Institute of Health Policy, Management and Evaluation, and Toronto Health Economics and Technology Assessment Collaborative, University of Toronto; S.R. Johnson, MD, PhD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, University of Toronto, and Division of Rheumatology, Mount Sinai Hospital, and Institute of Health Policy, Management and Evaluation, University of Toronto – sequence: 3 givenname: Arthur A surname: Bookman fullname: Bookman, Arthur A organization: S. Alharbi, MD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, and Division of Rheumatology, Mount Sinai Hospital, University of Toronto, and Taibah University; Z. Ahmad, MD, Division of Rheumatology, Mount Sinai Hospital, University of Toronto; A.A. Bookman, MD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network; Z. Touma, MD, PhD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, and Institute of Health Policy, Management and Evaluation, University of Toronto; J. Sanchez-Guerrero, MD, MSc, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, and Division of Rheumatology, Mount Sinai Hospital, University of Toronto; N. Mitsakakis, PhD, Institute of Health Policy, Management and Evaluation, and Toronto Health Economics and Technology Assessment Collaborative, University of Toronto; S.R. Johnson, MD, PhD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, University of Toronto, and Division of Rheumatology, Mount Sinai Hospital, and Institute of Health Policy, Management and Evaluation, University of Toronto – sequence: 4 givenname: Zahi surname: Touma fullname: Touma, Zahi organization: S. Alharbi, MD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, and Division of Rheumatology, Mount Sinai Hospital, University of Toronto, and Taibah University; Z. Ahmad, MD, Division of Rheumatology, Mount Sinai Hospital, University of Toronto; A.A. Bookman, MD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network; Z. Touma, MD, PhD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, and Institute of Health Policy, Management and Evaluation, University of Toronto; J. Sanchez-Guerrero, MD, MSc, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, and Division of Rheumatology, Mount Sinai Hospital, University of Toronto; N. Mitsakakis, PhD, Institute of Health Policy, Management and Evaluation, and Toronto Health Economics and Technology Assessment Collaborative, University of Toronto; S.R. Johnson, MD, PhD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, University of Toronto, and Division of Rheumatology, Mount Sinai Hospital, and Institute of Health Policy, Management and Evaluation, University of Toronto – sequence: 5 givenname: Jorge surname: Sanchez-Guerrero fullname: Sanchez-Guerrero, Jorge organization: S. Alharbi, MD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, and Division of Rheumatology, Mount Sinai Hospital, University of Toronto, and Taibah University; Z. Ahmad, MD, Division of Rheumatology, Mount Sinai Hospital, University of Toronto; A.A. Bookman, MD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network; Z. Touma, MD, PhD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, and Institute of Health Policy, Management and Evaluation, University of Toronto; J. Sanchez-Guerrero, MD, MSc, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, and Division of Rheumatology, Mount Sinai Hospital, University of Toronto; N. Mitsakakis, PhD, Institute of Health Policy, Management and Evaluation, and Toronto Health Economics and Technology Assessment Collaborative, University of Toronto; S.R. Johnson, MD, PhD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, University of Toronto, and Division of Rheumatology, Mount Sinai Hospital, and Institute of Health Policy, Management and Evaluation, University of Toronto – sequence: 6 givenname: Nicholas surname: Mitsakakis fullname: Mitsakakis, Nicholas organization: S. Alharbi, MD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, and Division of Rheumatology, Mount Sinai Hospital, University of Toronto, and Taibah University; Z. Ahmad, MD, Division of Rheumatology, Mount Sinai Hospital, University of Toronto; A.A. Bookman, MD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network; Z. Touma, MD, PhD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, and Institute of Health Policy, Management and Evaluation, University of Toronto; J. Sanchez-Guerrero, MD, MSc, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, and Division of Rheumatology, Mount Sinai Hospital, University of Toronto; N. Mitsakakis, PhD, Institute of Health Policy, Management and Evaluation, and Toronto Health Economics and Technology Assessment Collaborative, University of Toronto; S.R. Johnson, MD, PhD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, University of Toronto, and Division of Rheumatology, Mount Sinai Hospital, and Institute of Health Policy, Management and Evaluation, University of Toronto – sequence: 7 givenname: Sindhu R surname: Johnson fullname: Johnson, Sindhu R email: Sindhu.Johnson@uhn.ca, Sindhu.Johnson@uhn.ca organization: S. Alharbi, MD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, and Division of Rheumatology, Mount Sinai Hospital, University of Toronto, and Taibah University; Z. Ahmad, MD, Division of Rheumatology, Mount Sinai Hospital, University of Toronto; A.A. Bookman, MD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network; Z. Touma, MD, PhD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, and Institute of Health Policy, Management and Evaluation, University of Toronto; J. Sanchez-Guerrero, MD, MSc, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, and Division of Rheumatology, Mount Sinai Hospital, University of Toronto; N. Mitsakakis, PhD, Institute of Health Policy, Management and Evaluation, and Toronto Health Economics and Technology Assessment Collaborative, University of Toronto; S.R. Johnson, MD, PhD, Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, University Health Network, University of Toronto, and Division of Rheumatology, Mount Sinai Hospital, and Institute of Health Policy, Management and Evaluation, University of Toronto. Sindhu.Johnson@uhn.ca |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30008448$$D View this record in MEDLINE/PubMed |
| BookMark | eNo9j0trhDAcxHPY0n20x16LX8BtYqJJjmWxDxD2YAu9lCWPv10XNZKo4Lev0MdpmPkxA7NFq851gNAdwXsqpHy4-DOM7Z5wLFO6QhtMSRqTLPlYo20IF4xJxjJxjdYUYywYExv0mfe1hbZ2jfuaI9XZqBz9VE-qiVwVlXMYFmii0jTgXahD_B8VYz-GKPfzcIZWDS4s7jiBb1S_9DrrXQs36KpSTYDbX92h96f87fASF8fn18NjERuayiHWNAUBgJViCQemdWqMpERqK63GihgqjRDMCMozzXHFKwNWicxyUJJJluzQ_c9uP-oW7Kn3dav8fPr7mXwDgNdYZA |
| CitedBy_id | crossref_primary_10_1016_j_rdc_2023_01_001 crossref_primary_10_1016_j_rdc_2022_06_006 crossref_primary_10_1111_jdv_19912 crossref_primary_10_1007_s00296_019_04471_w crossref_primary_10_1186_s43166_024_00265_6 crossref_primary_10_1007_s40744_019_00181_8 crossref_primary_10_18786_2072_0505_2019_47_022 crossref_primary_10_4103_0973_029X_325259 crossref_primary_10_7326_aimcc_2024_0337 crossref_primary_10_1177_23971983221122673 crossref_primary_10_1007_s42399_024_01654_w crossref_primary_10_1093_mr_roab079 crossref_primary_10_1111_1756_185X_14130 crossref_primary_10_1016_j_revmed_2023_03_013 crossref_primary_10_1155_2019_8380214 crossref_primary_10_1002_acr_25235 crossref_primary_10_1002_iju5_12175 crossref_primary_10_1038_s41598_019_52920_0 crossref_primary_10_3390_jcm11185406 crossref_primary_10_1016_j_ajoc_2020_100967 crossref_primary_10_1097_MD_0000000000022582 crossref_primary_10_1016_j_lpm_2023_104221 crossref_primary_10_1136_bcr_2023_256858 crossref_primary_10_3390_diagnostics13050851 crossref_primary_10_1111_1756_185X_14225 crossref_primary_10_3899_jrheum_220877 crossref_primary_10_1007_s00296_018_4156_4 crossref_primary_10_3390_jpm12071123 crossref_primary_10_1016_j_semarthrit_2024_152472 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM |
| DOI | 10.3899/jrheum.170953 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
| DatabaseTitleList | MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| ExternalDocumentID | 30008448 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Canada |
| GeographicLocations_xml | – name: Canada |
| GroupedDBID | --- .55 .GJ 0R~ 123 18M 1KJ 3O- 4.4 53G 5RE 6PF AAFWJ AAQQT AAWTL ABCQX ABJNI ACGFO ACGFS ADCBC AENEX AFFNX AI. ALMA_UNASSIGNED_HOLDINGS BR6 CGR CUY CVF EBS ECM EIF EJD EMOBN F5P H13 HZ~ J5H L7B MJL NPM O9- P0W P2P RHI SJN TJE VH1 W2D X7M XBR XDU XOL YQJ ZGI ZXE ZXP |
| ID | FETCH-LOGICAL-c359t-b35e8ee0aa427e4bb5cc9319bd9db0a1c39c884c8376b70f7fceda86d7ea94942 |
| ISSN | 0315-162X |
| IngestDate | Mon Jul 21 06:05:59 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | MORTALITY COHORT STUDIES SYSTEMIC LUPUS ERYTHEMATOSUS SYSTEMIC SCLEROSIS SURVIVAL ANALYSIS |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c359t-b35e8ee0aa427e4bb5cc9319bd9db0a1c39c884c8376b70f7fceda86d7ea94942 |
| PMID | 30008448 |
| ParticipantIDs | pubmed_primary_30008448 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-10-01 |
| PublicationDateYYYYMMDD | 2018-10-01 |
| PublicationDate_xml | – month: 10 year: 2018 text: 2018-10-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Canada |
| PublicationPlace_xml | – name: Canada |
| PublicationTitle | Journal of rheumatology |
| PublicationTitleAlternate | J Rheumatol |
| PublicationYear | 2018 |
| SSID | ssj0016468 |
| Score | 2.419726 |
| Snippet | Systemic sclerosis (SSc) may overlap with systemic lupus erythematous (SLE). Little is known about the epidemiology, clinical characteristics, and survival of... |
| SourceID | pubmed |
| SourceType | Index Database |
| StartPage | 1406 |
| SubjectTerms | Adult Age Factors Antibodies, Anticardiolipin - blood Canada - epidemiology Female Follow-Up Studies Humans Hypertension, Pulmonary - etiology Kaplan-Meier Estimate Longitudinal Studies Lupus Coagulation Inhibitor - blood Lupus Erythematosus, Systemic - epidemiology Male Middle Aged Prevalence Proportional Hazards Models Scleroderma, Systemic - epidemiology Survival Rate Undifferentiated Connective Tissue Diseases - complications Undifferentiated Connective Tissue Diseases - epidemiology Undifferentiated Connective Tissue Diseases - mortality |
| Title | Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30008448 |
| Volume | 45 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS8MwFA6bwvBFvN8lD7529pK0zeMQRcTpgxNEkJGkKR24C9s60Ad_uydN23XeUF_KmjSh7ffl9Jyz5AtCJ5z6knFAwJMutcD_VxaLlGO5VNpx5EUBzdT52zf-5T25eqAPtdpbdXXJVDTl65frSv6DKpQBrnqV7B-QLTuFAvgN-MIREIbjrzA-n2_vamSU7lIY-TPjXxot8p6E4fus4FvYm1hl0XU6SidgA1-MZutwAme3M53aG0G7zxoGFbd1nKhUN6lm41vPCR-Lnskw93k537eV9A2DHrme3lOG_uDY54nX1niapON5QrUzhM5Ni6RXzUg4YTm3rVyJ5VDL8bNt0ksra0QjCzbZFZsJIZ7_lTHXyn_amGfP1XQCrYxXvQ6wGPUzZD3tyRCj2Plz7Qdt7aKqjuoQZehtU3WuJ_8PyifZQsryaYxCq76r04V7WkGNop8PsUnmo3TW0GqOEm4ZpqyjmhpsoEY7nz6xiZ6qhMFAGFwQBg9jXLADfyYMzgiDFwiDc8LggjBb6P7ivHN2aeX7a1jSo2xqCY-qUCmbc-IGighBpWRgkkXEImFzR3pMhiGRIXyERGDHQSxVxEM_ChRnhBF3Gy0NhgO1i3CohHADwm0lY2gAUbwXR3pfJ0c6sWByD-2YF9MdGRGVbvHK9r-tOUArc3YdouUYRq06AhdwKo4zpN4BPqlgSA |
| linkProvider | National Library of Medicine |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Epidemiology+and+Survival+of+Systemic+Sclerosis-Systemic+Lupus+Erythematosus+Overlap+Syndrome&rft.jtitle=Journal+of+rheumatology&rft.au=Alharbi%2C+Samar&rft.au=Ahmad%2C+Zareen&rft.au=Bookman%2C+Arthur+A&rft.au=Touma%2C+Zahi&rft.date=2018-10-01&rft.issn=0315-162X&rft.volume=45&rft.issue=10&rft.spage=1406&rft_id=info:doi/10.3899%2Fjrheum.170953&rft_id=info%3Apmid%2F30008448&rft_id=info%3Apmid%2F30008448&rft.externalDocID=30008448 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0315-162X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0315-162X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0315-162X&client=summon |